Announcement on the Progress of the Acquisition of Part of the Equity of Shanghai Xingke High Purity Solvent Co., Ltd. and Related Party Transaction
The Company's board of directors and all directors guarantee that this announcement contains no false or misleading statements, or significant omissions, and they shall bear individual and joint legal responsibility for the truthfulness, accuracy, and completeness of its content.
Overview of Related Party Transaction
Zhejiang Tianyu Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") held the 20th meeting of the Fifth Board of Directors on March 30, 2026, and approved the "Proposal on the Acquisition of Part of the Equity of Shanghai Xingke High Purity Solvent Co., Ltd. and Related Party Transaction." The Company signed a conditional "Equity Transfer Agreement" with the relevant transaction counterparties. The Company intends to acquire 87.8173% of the equity of Shanghai Xingke High Purity Solvent Co., Ltd. (hereinafter referred to as "Shanghai Xingke" or the "Target Company") held by Mr. Tu Yongjun and seven other counterparties for a transaction price of RMB 333,370.57 million in cash. Upon completion of this transaction, Shanghai Xingke will become a controlling subsidiary of the Company. For details, please refer to the "Announcement on the Acquisition of Part of the Equity of Shanghai Xingke High Purity Solvent Co., Ltd. and Related Party Transaction" (Announcement No.: 2026-014) disclosed by the Company on the Juchao Information Network on March 31, 2026.